Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company ...

THE European Medicines Agency on Friday recommended authorizing a twice-yearly injectable drug “lenacapavir” to prevent HIV and help end the virus’ transmission.

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Overview: Quality Chemicals supplies HIV medicines to 14 countries in the region, with 17 million treatments sold last year, ...

Thousands of Kenyans are set to benefit from the roll-out of Lenacapavir injectable HIV preventive drug. The drug is the ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

Scientific breakthroughs are fueling new hope in women’s health. But experts warn that persistent gaps in funding and access could stall that progress.

The very sayings that once shaped our conduct could be reimagined to reshape our mindsets: “Do not sweep the house at night, ...